ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology ...

The company is also progressing with its Alinity family of diagnostics. With several recent large contract wins, Alinity is ...

Abbott Laboratories will report earnings pre-market on January 22, with an earnings consensus of $1.04 per share. See why I ...

Abbott Laboratories engages in the discovery ... Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products ...

At Abbott, we’re keeping people healthy with innovative medical device technologies that help advance the future of cardiovascular care and improve patient lives. With essential devices ...

In our view, the biggest risks Abbott faces include ongoing difficulties with its left ventricular assist devices, and the potential commercial success of its Libre franchise, which includes planned ...

Abbott (NYSE: ABT) will announce its fourth-quarter 2024 financial results on Wednesday, Jan. 22, before the market opens.

Evercore ISI raised the firm’s price target on Abbott (ABT) to $136 from $128 and keeps an Outperform rating on the shares. In the firm’s 2025 ...